Skip to main content
profileAnalyst coverage5 yr. financialspremium researchdividendsadv. chartsearningsoptionsprice historyeventsinsiders

ZIOPHARM Oncology, Inc. News

Why 2018 will be better for biotech deals than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Here's what you need to know now for Monday, Jan. 22.

Immunotherapy stocks power higher on Celgene-Juno deal

Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.

More Immunotherapy Buyouts Likely After Kite Sale

More Immunotherapy Buyouts Likely After Kite Sale

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.

Breaking News

Disney Mobile Game Opens Up a New Universe

Familiar Disney characters populate an alternate reality in new interactive game.

Birth Control Stocks May Benefit From the Reversal of Roe v. Wade

The historic Supreme Court decision may force women to make different choices.

Barstool's Portnoy Takes a Surprising Stand on a Key Political Issue

The outspoken Republican with a platform voices his opinion on the state of democracy moving to the right.

McDonald's Brings Back a Classic Menu Item (with a Catch)

You never know what the fast-food chain might bring back or create a new version of.